Given the potential suppressive role for THRB over disease-promoting core gene targets, and because THRB agonists are in current clinical trials for MASLD, we examined THRB regulon activity in more detail. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatotic liver disease.